Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia

Yun-Gyoo Lee¹, Inho Kim², Somi Oh², Dong-Yeop Shin², Youngil Koh², and Keun-Wook Lee³

INTRODUCTION

Acute myeloid leukemia (AML) is a group of hematopoietic neoplasms featuring impaired hematopoiesis and bone marrow failure caused by clonal expansion of undifferentiated myeloid precursors. AMLs are frequently found to have recurrent chromosomal aberrations and gene mutations [1]. Even in AML cases with normal cytogenetics, most carry driver mutations relevant to patient clinical outcomes [1]. In the context of posttranscriptional regulation, microRNAs, a class of small noncoding RNAs, regulate the expression of other genes by targeting over 60% of protein-coding transcripts [2].

Compelling evidence has indicated that microRNAs are key regulators of hematopoiesis [3,4]. In AML, several studies have shown that differential microRNA expression is associated with cytogenetic aberrations and impacts clinical outcomes [5-8]. Recently, there has been growing interest in using next-generation sequencing (NGS) to profile microRNAs. Sequencing provides us...
with the potential to verify novel microRNAs associated with a disease of interest. However, quantitative microRNA sequencing has not been well-evaluated in AML.

In the present study, we analyzed differential microRNA expression by quantitative small RNA NGS using duplicate marrow samples from individual AML patients, and evaluated those microRNAs relevant to AML pathogenesis.

**METHODS**

**Patient samples**

All clinical samples included in this study were obtained from AML patients ≥ 20 years of age who underwent bone marrow biopsy before treatment; informed consent was obtained in accordance with the Declaration of Helsinki. Regarding paired samples, we obtained marrow samples at two different time points: initial diagnosis and first complete remission status. Control samples (normal marrow) were collected from the five patients who underwent bone marrow biopsy to rule out primary hematologic disorders and were found normal upon marrow evaluation. The study protocol was approved by the Institutional Review Board at Seoul National University Hospital (1106-092-366).

**Total RNA isolation**

Briefly, total RNA from marrow mononuclear cells was isolated using Trizol reagent (Invitrogen, Paisley, UK) according to manufacturer instructions. RNA quality was analyzed with a Bioanalyzer and RNA Nano Chips (Agilent Technologies, Santa Clara, CA, USA). Quantification of total RNA yield was determined using QuantiT RiboGreen RNA Reagent and Kit (RiboGreen, Invitrogen).

**Small RNA library preparation and sequencing**

NGS was performed by LAS Inc. (Gimpo, Korea; http://www.lascience.co.kr/). Small RNAs were sequenced using a TruSeq Small RNA Sequencing Kit (Illumina, San Diego, CA, USA) according to manufacturer instructions. All samples were sequenced on an Illumina NextSeq 500 Sequencer using a 75-cycle High Output Kit.

With the binary base call files from the sequencer, conversion into FASTQ format and de-multiplexing were performed using Illumina bcl2fastq2 software version 2.17 (http://support.illumina.com/downloads/). Adapter trimming was performed using the FASTQ Toolkit App version 1.0 of Illumina BaseSpace (http://basespace.illumina.com/apps/). Quality of the sequenced reads before and after adapter trimming was evaluated using FastQC software version 0.11.4 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Cleaned sequences were aligned to the most recent mirBASE database release 21 (http://mirBase.org/) [9] using the Small RNA App version 1.0 of Illumina BaseSpace. Quantification of microRNA expression was performed by counting aligned reads to microRNA genes.

**Statistical analysis**

To identify potential microRNAs that were the most relevant to AML pathogenesis, a three-step approach was employed as follows:

- **Step 1:** comparison of microRNA expression between 14 AML patients and 5 normal marrow controls (Fig. 1A).
- **Step 2:** comparison of microRNA expression using paired samples from the time of diagnosis and complete remission for each patient (Fig. 1B).
- **Step 3:** testing of the association of microRNA expression with different counts of bone marrow blasts (Fig. 1C).

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Preplanned comparison for differential microRNA (miRNA) expression. (A) Acute myeloid leukemia (AML)-related miRNA, (B) paired sample analysis, and (C) leukemia burden-related miRNA.
Statistical analyses were completed using Stata version 12.0 software (StataCorp LP, College Station, TX, USA). A Student $t$ test was used to determine statistically significant differences between comparison groups. $p$ values of less than 0.05 were considered statistically significant. Pearson’s correlation coefficient was calculated and analyzed to evaluate the linear relationship between the expression of a specific microRNA and disease burden (the lowest and the highest blast counts in bone marrow).

**RESULTS**

From March 2013 to August 2015, we enrolled 16 AML patients whose paired samples from the time points of diagnosis and complete remission were available as well as six patients who were confirmed to have normal marrow. Among the 16 paired samples from AML marrow, eight were eligible for analysis after evaluating the quality of extracted RNA. Of the remaining eight paired samples, six single samples obtained at diagnosis were included in further analyses. Among the six samples from normal marrow, five were enrolled as normal controls except one which RNA was not qualified for sequencing; four patients were diagnosed with immune thrombocytopenia and one was diagnosed with normal reactive marrow.

The clinical and molecular characteristics of enrolled patients are shown in Table 1. The median age of the 14 AML patients was 53 years (range, 20 to 78) and seven (50%) were men. Eight patients (57%) had normal karyotypes.

**Descriptive statistics of microRNA differential expression**

The number of reads that mapped to alleged microRNAs in the miRBase database ranged from 2,816,113 to 13,405,453. All microRNA mapping reads belonged to 511 unique microRNA families.

**Table 1. Clinical characteristics of study patients**

| Sample | ID   | Age, yr | Sex | Chromosomal abnormality | Bone marrow blasts, % |
|--------|------|---------|-----|------------------------|-----------------------|
| Paired sample of AML diagnosis and initial complete remission | 1-1/1-2 | 55 | M | t(8:21), –Y | 76/3 |
| | 2-1/2-2 | 69 | F | t(7:11) | 22/0 |
| | 3-1/3-2 | 20 | F | Normal | 69/1 |
| | 4-1/4-2 | 49 | F | t(8:21) | 33/0 |
| | 5-1/5-2 | 52 | M | t(8:21) | 50/1 |
| | 6-1/6-2 | 43 | M | Normal | 53/0 |
| | 7-1/7-2 | 25 | M | Normal | 71/4 |
| | 8-1/8-2 | 60 | F | t(6:9) | 58/5 |
| Solitary sample of AML diagnosis | 9 | 58 | M | Normal | 20 |
| | 10 | 65 | F | del(q)(q13q22) | 21 |
| | 11 | 50 | F | Normal | 22 |
| | 12 | 54 | M | Normal | 90 |
| | 13 | 78 | M | Normal | 59 |
| | 14 | 45 | F | Normal | 74 |
| Normal marrow control | 15 | 69 | F | Immune thrombocytopenia | 1 |
| | 16 | 37 | M | Immune thrombocytopenia | 3 |
| | 17 | 33 | F | Immune thrombocytopenia | 0 |
| | 18 | 60 | M | Immune thrombocytopenia | 2 |
| | 19 | 63 | F | Normal | 1 |

AML, acute myeloid leukemia; M, male; F, female.
Twelve microRNAs were identified as AML relevant microRNA

To establish whether the microRNA profiles of AML cells and normal controls may differ, we first compared the 14 AML samples and five normal controls (Fig. 1A). Upon initial comparison, 19 microRNAs were found to be differentially expressed in AML as compared to normal controls. Twelve of these microRNAs had higher expression levels in AML than in normal controls (Table 2).

Six microRNAs were related to leukemia activity

Approximately 80% of patients with AML achieve complete remission with conventional induction chemotherapy [10]. In complete remission, the total body leukemic cell population is reduced from approximately 10^{12} to below approximately 10^{9} cells. Likewise, we hypothesized that expression of AML-relevant microRNAs could substantially decrease from the time of initial diagnosis to remission. Importantly, we assert that using a paired sample from the same patient can minimize interpersonal variation. Therefore, we compared the expression of microRNA between initial diagnosis and complete remission in eight AML paired samples (Fig. 1B). Six microRNAs had higher expression levels at initial AML diagnosis as compared to initial complete remission (Table 2).

Four microRNAs according to AML tumor burden

In the context of the third comparison (Fig. 1C), we assert that certain microRNAs correlated with marrow blasts counts may be relevant to AML. Indeed, we detected positive correlations between higher expression levels of mir-221, mir-146, and mir-155 with higher marrow blast counts, with Pearson’s correlation coefficients of \( r = 0.680, p < 0.001 \), \( r = 0.613, p = 0.001 \), and \( r = 0.592, p < 0.001 \) (Table 2).
was downregulated in patients with leukemia remission status after inhibition of proliferation.

A functional relationship exists between mir-221/222 and p27\textsuperscript{Kip1}, a key regulator of the cell cycle; a known target of mir-221/222 includes a regulator of p27\textsuperscript{Kip1}, cyclin-dependent kinase inhibitor 1B (CDKN1B) [15,16]. Regulation of p27\textsuperscript{Kip1} expression by aberrant mir-221/222 expression promotes cancer cell progression [17]. Thus, the use of synthetic inhibitors of mir-221/222 as a putative oncogene might be a promising approach to cancer treatment [18-20].

The mir-181 family, which was included in comparisons 1 and 2, was the first microRNA family discovered to be specifically expressed in hematopoietic cells [21]. Accumulating data has shown that the mir-181 family plays a critical role in regulating normal cell differentiation and leukemogenesis, particularly in AML [21,22]. A number of studies have shown that mir-181 expression is correlated to cytogenetic and molecular subtypes of AML and has potential as a diagnostic marker for AML [23-25]. Moreover, mir-181 family members have been consistently reported as prognostic markers in AML patients [8,26-28]. Based on these reports, studies on chemotherapy combined with strategies targeting mir-181 have been conducted as a new strategy for AML therapy.

Another microRNA that was included in comparisons 1 and 2, mir-3154, has not been reported in scientific literature to our knowledge. Subsequent studies on the role of mir-3154 for AML pathogenesis are warranted.

Small microRNA sequencing by NGS has many advantages. One clear advantage is the ability to find novel microRNAs. Additionally, because microRNAs have relatively short sequence of 18 to 24 nucleotides, NGS could sequence microRNAs that are vulnerable to rapid degradation [29]. However, there is no evidence that NGS is superior to microarray or real-time polymerase chain reaction [30].

Our findings are limited by selection bias with respect to a 29% sequencing failure rate and small sample sizes. Additionally, the microRNAs reported in the present study need to be validated in independent datasets, and functional characteristics must be elucidated.

Our results demonstrate that mir-221 and mir-181 are selectively enriched in AML marrow and reflect disease activity. A mir-3154 is a novel microRNA that is relevant to AML but requires further validation.

**KEY MESSAGE**

1. Our study showed that mir-221 and mir-181 are selectively enriched in acute myeloid leukemia (AML) marrow and reflect disease activity.
2. It is meaningful that our results are reproduced in a new methodology (quantitative small RNA next-generation sequencing, duplicate marrow samples from individual AML patients) with small sample size.
3. A mir-3154 is a novel microRNA that is relevant to AML but requires further validation.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2011-0024046 to NRF-2015-0024046), and was supported by the Cooperative Research Program of Basic Medical Science and Clinical Science from Seoul National University College of Medicine (grant no. 800-20140171).

**REFERENCES**

1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leuke- mia. N Engl J Med 2016;374:2209-2221.
2. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Ge- nome Res 2009;19:92-105.
3. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug develop- ment. Nat Rev Drug Discov 2013;12:847-865.
4. Larsen MT, Hager M, Glenthoj A, et al. miRNA-130a reg- ulates C/EBP-\(\varepsilon\) expression during granulopoiesis. Blood 2014;123:1079-1089.
5. Cammarata G, Augugliaro I, Salemi D, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010;85:331-339.
6. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1919-1928.

7. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008;111:3183-3189.

8. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2010;115:3183-3189.

9. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42(Database issue):D68-D73.

10. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373:1136-1152.

11. Rommer A, Steinleitner K, Hackl H, et al. Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer 2013;13:364.

12. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. MicroRNAs in cancer management. Lancet Oncol 2012;13:e249-e258.

13. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010;115:3959-3969.

14. Gimenes-Teixeira HL, Lucena-Araujo AR, dos Santos GA, et al. Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol 2013;2:24.

15. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005;102:18081-18086.

16. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102:18074-18080.

17. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3676-3686.

18. Gallo Cantafio ME, Nielsen BS, Mignogna C, et al. Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates. Mol Ther Nucleic Acids 2016;5. https://doi.org/10.1038/mtna.2016.36.

19. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010;107:264-269.

20. Moses BS, Evans R, Slone WL, et al. Bone marrow microenvironment niche regulates miR-221/222 in acute lymphoblastic leukemia. Mol Cancer Res 2016;14:909-919.

21. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-86.

22. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008;15:352-358.

23. Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-McIver A, Young BD. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007;21:912-916.

24. Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007;104:19971-19976.

25. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008;105:15535-15540.

26. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:5257-5264.

27. Li Z, Huang H, Li Y, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181a is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012;119:2314-2324.

28. Hickey CJ, Swind S, Radomska HS, et al. Lenalidomide-mediated enhanced translation of C/EBPα-390 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013;121:159-169.

29. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 2011;12:87-98.

30. Git A, Dvinge H, Salmon-Divon M, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010;16:991-1006.